[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR201105367A2 - A dry powder formulation with improved flow properties. - Google Patents

A dry powder formulation with improved flow properties.

Info

Publication number
TR201105367A2
TR201105367A2 TR2011/05367A TR201105367A TR201105367A2 TR 201105367 A2 TR201105367 A2 TR 201105367A2 TR 2011/05367 A TR2011/05367 A TR 2011/05367A TR 201105367 A TR201105367 A TR 201105367A TR 201105367 A2 TR201105367 A2 TR 201105367A2
Authority
TR
Turkey
Prior art keywords
dry powder
powder formulation
flow properties
improved flow
present
Prior art date
Application number
TR2011/05367A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/05367A priority Critical patent/TR201105367A2/en
Priority to TR2012/05852A priority patent/TR201205852A2/en
Priority to PCT/TR2012/000091 priority patent/WO2012166070A1/en
Priority to PCT/TR2012/000096 priority patent/WO2013009271A1/en
Publication of TR201105367A2 publication Critical patent/TR201105367A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş; astım ve KOAH gibi solunum yolları hastalıklarında kullanılmak üzere geliştirilmiş yeni bir kuru toz formülasyon ile ilgilidir.The present invention includes; The present invention relates to a new dry powder formulation developed for use in respiratory diseases such as asthma and COPD.

TR2011/05367A 2011-06-02 2011-06-02 A dry powder formulation with improved flow properties. TR201105367A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2011/05367A TR201105367A2 (en) 2011-06-02 2011-06-02 A dry powder formulation with improved flow properties.
TR2012/05852A TR201205852A2 (en) 2011-06-02 2012-05-21 Improved new dry powder formulation.
PCT/TR2012/000091 WO2012166070A1 (en) 2011-06-02 2012-05-28 Dry powder formulation with improved flow characteristics
PCT/TR2012/000096 WO2013009271A1 (en) 2011-06-02 2012-05-31 New improved dry powder formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2011/05367A TR201105367A2 (en) 2011-06-02 2011-06-02 A dry powder formulation with improved flow properties.

Publications (1)

Publication Number Publication Date
TR201105367A2 true TR201105367A2 (en) 2012-12-21

Family

ID=46456987

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/05367A TR201105367A2 (en) 2011-06-02 2011-06-02 A dry powder formulation with improved flow properties.

Country Status (2)

Country Link
TR (1) TR201105367A2 (en)
WO (1) WO2012166070A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP3823602A4 (en) * 2018-07-20 2022-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising anti-bacterial agents
IT201900002857A1 (en) * 2019-02-27 2020-08-27 Ntc S R L Process of filling containers with a powder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
GB0219513D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
EP2221048A1 (en) * 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
EP2563364A1 (en) * 2010-04-26 2013-03-06 Mahmut Bilgic Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
WO2011160920A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug

Also Published As

Publication number Publication date
WO2012166070A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
PL2892808T3 (en) Stabilized aggregates and other materials and structures for purposes including, but not limited to, energy absorption
FR3000095B1 (en) COMPOSITION COMPRISING 2,3,3,3-TETRAFLUOROPROPENE AND 1,2-DIFLUOROETHYLENE
CO6831975A2 (en) Immunoconjugates, compositions to prepare them, methods to prepare them and use
CL2015000826A1 (en) Composition of fluorine-containing non-aqueous coating material, coating methods and the use of the coating material composition
TR201909788T4 (en) C4-monomethyl triterpenoid derivatives and their usage methods.
TWD160007S (en) Vehicle hood
CL2014002037A1 (en) Powdered mineral material with high dispersibility, and use of said mineral powder material
CO6950497A2 (en) Compounds of substituted 1,2,5-oxadiazole and their use as herbicides
JP2015513329A5 (en) How to determine hand hygiene compliance
TR201903918T4 (en) Compositions containing a dispersing agent and their preparation.
BR112014017481A2 (en) dry powder formulation for use in a dry powder inhaler, dry powder inhaler and use of a formulation
AR092882A1 (en) 1,2,4-triazin-3,5-dion-6-carboxamides and their use as herbicides
TR201109439A2 (en) Inhalation device with pump.
BR112014005406A2 (en) vaccine composition and its use
TWD169341S (en) Portion of a sheet material for air filter
BR112014014504A2 (en) particle use
TR201901651T4 (en) Aging trackers.
TR201205852A2 (en) Improved new dry powder formulation.
BR112013023575A2 (en) “octahydrothienoquinoline derivative, pharmaceutical composition comprising the derivative, and use thereof”
TR201105367A2 (en) A dry powder formulation with improved flow properties.
TR201100148A2 (en) Stable acarbose formulations.
IN2013CH01374A (en)
BR112015004494A2 (en) permeability flow cell and hydraulic conductance system
BR112015004348A2 (en) permeability flow cell and hydraulic conductance system
TWD158777S (en) Table